iBio initiates non-human primate study of IBIO-610

iBio (IBIO) announced the initiation of a NHP study for its Activin E engineered antibody candidate, now named IBIO-610. This preclinical study will evaluate the pharmacokinetics and early signs of efficacy of IBIO-610 in obese and elderly NHPs, including its impact on fat and body composition. The study initiation follows a successful scale-up in production and encouraging preclinical results demonstrating a 26% reduction in fat, and synergistic effects with GLP-1 therapy in diet-induced obese mice, where the fat-selective weight loss increased to 77%. Initial data from the NHP study are expected by early Q4. The NHP study launch follows additional positive preclinical data to be presented at the American Diabetes Association’s 85th Scientific Sessions, taking place June 20-23 in Chicago. This poster presentation expands on recent in vivo findings, which also demonstrated a significant 31% reduction in subcutaneous fat and increased to 74% reduction in subcutaneous fat when IBIO-610 was combined with a GLP-1 receptor agonist. The new data show IBIO-610 can not only enhance GLP-1-driven overall weight loss but also prevent weight-regain in DIO mice after GLP-1 therapy discontinuation. This is especially important, as the post-treatment period is typically marked by rapid weight rebound in humans